

Ariadna PadullÃ©s

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7919010/publications.pdf>

Version: 2024-02-01

16
papers

192
citations

1307366

7
h-index

1058333

14
g-index

16
all docs

16
docs citations

16
times ranked

381
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of β -lactam antibiotic concentration in human plasma. <i>Clinica Chimica Acta</i> , 2017, 468, 215-224.	0.5	56
2	Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. <i>International Journal of Infectious Diseases</i> , 2020, 101, 290-297.	1.5	33
3	Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs. <i>Antibiotics</i> , 2021, 10, 53.	1.5	19
4	De novo use of a generic formulation of tacrolimus versus reference tacrolimus in kidney transplantation: evaluation of the clinical results, histology in protocol biopsies, and immunological monitoring. <i>Transplant International</i> , 2015, 28, 1283-1290.	0.8	13
5	Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection. <i>Antibiotics</i> , 2021, 10, 446.	1.5	13
6	External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 120-129.	1.0	12
7	Measurement of ceftazidime concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Application to critically ill patients and patients with osteoarticular infections. <i>Biomedical Chromatography</i> , 2016, 30, 410-418.	0.8	11
8	Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 102-110.	1.0	8
9	Developments in renal pharmacogenomics and applications in chronic kidney disease. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 251.	0.4	7
10	Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use. <i>Infection</i> , 2018, 46, 239-244.	2.3	7
11	LB3. Daptomycin Plus Fosfomycin vs. Daptomycin Monotherapy for Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia: A Multicenter, Randomized, Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S760-S760.	0.4	4
12	Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant <i>Pseudomonas aeruginosa</i> : A Prospective Cohort Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 587-599.	0.6	3
13	Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 932-939.	0.7	3
14	Association between infliximab concentrations and clinical response in psoriasis: a prospective cohort study. <i>Journal of Dermatological Treatment</i> , 2021, 32, 180-187.	1.1	2
15	Impact of comprehensive molecular testing to reduce antibiotic use in community-acquired pneumonia (RADICAP): a randomised, controlled, phase IV clinical trial protocol. <i>BMJ Open</i> , 2020, 10, e038957.	0.8	1
16	Infectious diseases experts as part of the antibiotic stewardship team in primary care: protocol for a cluster-randomised blinded study (IDASP). <i>BMJ Open</i> , 2021, 11, e053160.	0.8	0